Back to Journals » Drug Design, Development and Therapy » Volume 11

Safety of switching from brand-name to generic levetiracetam in patients with epilepsy

Authors Bosak M, Słowik A, Turaj W

Received 29 March 2017

Accepted for publication 11 July 2017

Published 3 August 2017 Volume 2017:11 Pages 2287—2291

DOI https://doi.org/10.2147/DDDT.S138270

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 3

Editor who approved publication: Professor Manfred Ogris

Magdalena Bosak, Agnieszka Słowik, Wojciech Turaj

Department of Neurology, Jagiellonian University Medical College, Kraków, Poland

Purpose: The approach to the use of generic antiepileptic drugs has recently evolved from major concern to general acceptance, but the evidence related specifically to the safety of switching from brand-name to generic levetiracetam (LEV) is scarce. The aim of the study was to assess the risk of increased frequency of seizures or other adverse events after replacement of a brand-name LEV with a generic one.
Patients and methods: This retrospective analysis included 159 patients treated with LEV in a tertiary outpatient epilepsy clinic. We included all patients diagnosed with epilepsy who were treated with LEV as at March 1, 2013. Most patients were forced to switch to the generic LEV because of the sudden rise in cost of the branded LEV. We recorded data on age, sex, age at onset of epilepsy, type of epilepsy, and its treatment. We analyzed data from one visit before potential switching and from two visits after the potential switching. The interval between visits was typically 3 months. We registered an increase in the frequency of seizures and in the occurrence of adverse events.
Results: Among 151 subjects who switched to generic LEV after March 1, 2013, increased frequency of seizures was noted in 9 patients (6%) during the first follow-up visit. Patients with increased frequency of seizures did not differ from other patients regarding sex, age, age at the onset of epilepsy, and the median dose of LEV before switching or the median duration of treatment with LEV before switching. Two patients returned to brand-name LEV. Adverse events were noted in six other patients (4%) and included somnolence, irritability, or dizziness.
Conclusion: Switching from brand-name to generic LEV is generally safe.

Keywords: levetiracetam, generic, branded, epilepsy, switching, adverse event
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Depressogenic medications and other risk factors for depression among Polish patients with epilepsy

Bosak M, Turaj W, Dudek D, Siwek M, Szczudlik A

Neuropsychiatric Disease and Treatment 2015, 11:2509-2517

Published Date: 30 September 2015